News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioAxone Therapeutic Inc. Appoints Patrick Tremblay Vice President Research & Development


11/29/2005 10:44:39 AM

MONTREAL, Nov. 28 /PRNewswire/ - BioAxone announced today that it has appointed Dr. Patrick Tremblay Vice President Research & Development (R&D), effective December 1, 2005. Dr. Tremblay joins BioAxone from Neurochem Inc. where he served as Director of Pharmacology. He succeeds BioAxone's CSO, Dr. Lisa McKerracher, who remains an active member of the Company's Board of Directors.

"Since initiating its clinical phase I/IIa trial for acute spinal cord injury in February of this year, BioAxone has focused its preclinical efforts on using Rho inactivation antagonists as a new therapeutic approach for the treatment of age-related macular degeneration and glaucoma. Dr. Tremblay's broad expertise in neurodegenerative diseases and proven leadership in biopharmaceutical R&D will be key in assuring that BioAxone advances this program to IND status before the end of 2006", said Dr. Bobe, BioAxone's President and CEO. After obtaining his Ph.D. in molecular biology from the University of Montreal in 1990, Dr. Tremblay spent three years as a postdoctoral research fellow at the Max Planck Institute in Germany where he worked with Dr. Peter Gruss, current president of the Max Planck Society. He then moved to the University of California in San Francisco to work on neurodegenerative diseases caused by prions with Dr. Stanley Prusiner, Nobel Laureate of Medicine and Physiology (1997). In 2001, Dr. Tremblay joined Neurochem, where he was responsible for the development of small therapeutic molecules for the treatment of amyloid diseases such as Alzheimer's disease.

About BioAxone

BioAxone Therapeutic Inc. is a privately owned neuroscience company specializing in the development and commercialization of proprietary technologies that target Rho signaling.

BioAxone is a product-driven company, with one product in clinical development for the treatment of acute spinal cord injury and several product candidates in preclinical phase for the treatment of macular degeneration and glaucoma. The Company has demonstrated expertise in recombinant protein product development and has a focused small molecule program. BioAxone was established in April 2000 and is headquartered in Montreal, Canada.

BIOAXONE THERAPEUTIC INC.

CONTACT: Dr Frank Bobe, President and CEO, BioAxone Therapeutic Inc.,(514) 282-9990, info@bioaxone.com; www.bioaxone.com


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES